New Indication for Ranibizumab Granted in EU
The European Commission has granted Novartis a new,
broader indication for ranibizumab (Lucentis; Genentech)
to treat patients with visual impairment due to diabetic
macular edema, according to a company news release.
The approval of Lucentis was based on data from two
Novartis-sponsored clinical trials, RESTORE and RE...